Access Pharmaceuticals Announces Preliminary Fourth Quarter Revenue Results;; MuGard Product Revenue Increases 400% Quar

^{Published on 2012-03-05 05:35:38 - Market Wire}
 

Access Pharmaceuticals Announces Preliminary Fourth Quarter Revenue Results; MuGard Product... -- DALLAS and NEW YORK, March 5, 2012 /PRNewswire/ --

Company Cowen Health Care Conference Presentation this Week to Include Update on Commercial Achievements and Review of Preliminary Quarter Results

Company's Webcast Presentation, Wednesday, March 7th at 8:00am EDT

DALLAS and NEW YORK, March 5, 2012 /PRNewswire/ -- [ ACCESS PHARMACEUTICALS, INC. ] (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011.  Fourth quarter MuGard product sales increased 400% over third quarter product sales. Full year 2011 revenues, including license revenues, royalties and research agreements, increased 284% over 2010 figures. Access attributes growth in revenues to increased adoption of MuGard, as well as significant expansion by pharmacy benefit managers and payers to include MuGard in their benefit plans for reimbursement.

Wednesday morning, the Company will present at the Cowen and Company 32nd Annual Health Care Conference, at The Boston Marriott Copley Place in Boston, MA.  Mr. Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation updating investors on recent commercial advancements within its lead program for oral mucositis, [ MuGard ], and other product programs.  

A live webcast of the audio presentation and company slide deck can be accessed via the following link during the presentation time: [ http://wsw.com/webcast/cowen6/accp/ ].

About MuGard:

[ MuGard ] is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of [ oral mucositis ], a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.  For more information, please visit [ www.MuGard.com ].

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include [ MuGard™ ] ([ www.MuGard.com ]), which has received FDA marketing clearance for the management of patients with mucositis, [ ProLindac™, ] a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and [ Thiarabine ]™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including [ CobaCyte™-mediated targeted delivery ] and [ CobOral-oral drug delivery ], its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at [ www.accesspharma.com ].

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.

RELATED LINKS
[ http://www.accesspharma.com ]